We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Sequencing Technology Has Unlimited Potential in Clinical Application
Industry Insight

Sequencing Technology Has Unlimited Potential in Clinical Application

Sequencing Technology Has Unlimited Potential in Clinical Application
Industry Insight

Sequencing Technology Has Unlimited Potential in Clinical Application


Want a FREE PDF version of This Industry Insight?

Complete the form below and we will email you a PDF version of "Sequencing Technology Has Unlimited Potential in Clinical Application"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

With the development of science, traditional Sanger sequencing has failed to meet new requirements of low cost, high throughput and speed. Under such a circumstance, the next-generation sequencing technology (second-generation sequencing) appears. As an emerging industry, the next-generation sequencing technology can be applied in clinical genetic testing, health industry, industrial and agricultural use of gene-oriented study as well as scientific research and development.

In recent years, with the discovery and promotion of second-generation sequencing technology, gene sequencing speed has increased greatly whilst also achieving a substantial decline in costs, making the large-scale application of genome sequencing possible. Now, the cost of personal whole genome sequencing is about $5,000, and is expected to decreased to less than $ 1,000 in the next few years.

The rapid development of sequencing technology will promote massive accumulation of DNA sequencing data, accompanied by the accumulation of  corresponding individual diseases, signs and other data at the same time. When we accumulate enough data, how to understand these data will be critical. On the micro level, generations of molecular biologists’ studying the effects of apparent biological traits genes exert on utilizing technologies like gene knockout have made breakthroughs in many crucial aspects. On the macro level, statistics and other data analysis techniques are introduced to study the relationship between gene sequences and biological phenotypes. The accumulation of basic scientific research gradually brings breakthroughs in clinical applications.

There are now two types of main clinical applications, one aims at disease screening of ordinary people. It infers people’s future risks of getting cancer by measuring the known genes associated with a disease loci. The other aims at the diagnosis cancer and other deadly diseases. It helps to select a series of therapeutics or highligts the most effective one for certain patients by testing the loci of certain genes.

Data from BBC research shows that total global gene sequencing market increased from $7.941million in 2007 to $4.5 billion in 2013, and will reach $11.7 billion in the year of 2018 with the CAGR up to 21.2%.

Currently, the market for next-generation sequencing platforms is dominated by several major manufacturers, including the Illumina, Ion Torrent / Life Technologies (was the acquisition of Thermo Fisher in 2014), 454 Life Sciences / Roche and other smaller companies like Creative Biolabs and CD Genomics.
Advertisement